Patents by Inventor Gyoonhee Han

Gyoonhee Han has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11649231
    Abstract: The present invention relates to a novel compound as an mTOR inhibitor and a use thereof and, more specifically, to a novel compound represented by formula 1 that exhibits mTOR inhibitory activity and a pharmaceutical composition comprising same as an active ingredient for preventing or treating brain diseases associated with an mTOR pathway.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: May 16, 2023
    Assignees: MEDICINAL BIOCONVERGENCE RESEARCH CENTER, INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Sunghoon Kim, Jong Hyun Kim, Gyoonhee Han, Jung Min Han, Chulho Lee
  • Patent number: 11459311
    Abstract: A composition for promoting longitudinal bone growth, according to the present invention, promotes the proliferation of the chondrocytes and the differentiation of the osteoblasts and has effects of simultaneously increasing longitudinal bone length and thickness (bone density), and thus has an advantage of being widely prescribable to various age groups, thereby being usable as a pharmaceutical composition for promoting the growth of longitudinal bone length and thickness. An indirubin derivative according to the present invention has prevention or treatment effects through oral administration. In addition, unlike conventional therapeutic agents, the pharmaceutical composition for preventing or treating bone diseases of the present invention is a stable compound, which is known to be substantially noncytotoxic to the human body, and is a material of which adverse effects have not been identified and has excellent treatment effects for bone diseases and osteogenesis imperfecta.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: October 4, 2022
    Assignee: CK REGEON INC.
    Inventors: Kang-Yell Choi, Gyoonhee Han, Jeong-Ha Hwang, Sehee Choi, Changmok Oh
  • Publication number: 20220193041
    Abstract: The present invention relates to a novel compound, and a composition for preventing or treating of respiratory disease comprising the novel compound, E- or Z-isomer thereof, optical isomer thereof, a mixture of two isomers thereof, precursor thereof, pharmaceutically acceptable salt thereof or solvate thereof as an active ingredient.
    Type: Application
    Filed: April 1, 2020
    Publication date: June 23, 2022
    Inventors: Jae Young CHOI, Gyoonhee HAN, Wan NAMKUNG, Sung Ha PARK, Moo Suk PARK
  • Publication number: 20210292314
    Abstract: The present invention relates to a novel compound as an mTOR inhibitor and a use thereof and, more specifically, to a novel compound represented by formula 1 that exhibits mTOR inhibitory activity and a pharmaceutical composition comprising same as an active ingredient for preventing or treating brain diseases associated with an mTOR pathway.
    Type: Application
    Filed: October 26, 2020
    Publication date: September 23, 2021
    Inventors: Sunghoon Kim, Jong Hyun Kim, Gyoonhee Han, Jung Min Han, Chulho Lee
  • Publication number: 20200223824
    Abstract: A composition for promoting longitudinal bone growth, according to the present invention, promotes the proliferation of the chondrocytes and the differentiation of the osteoblasts and has effects of simultaneously increasing longitudinal bone length and thickness (bone density), and thus has an advantage of being widely prescribable to various age groups, thereby being usable as a pharmaceutical composition for promoting the growth of longitudinal bone length and thickness. An indirubin derivative according to the present invention has prevention or treatment effects through oral administration and has an excellent competitive price unlike conventional hormone-based therapeutic agents.
    Type: Application
    Filed: April 10, 2018
    Publication date: July 16, 2020
    Inventors: Kang-Yell Choi, Gyoonhee Han, Jeong-Ha Hwang, Sehee Choi, Changmok Oh
  • Publication number: 20070066577
    Abstract: A novel benzoxazole derivative of formula (I) or a pharmaceutically acceptable salt thereof is effective for inhibiting 5-lipoxygenase which is useful for preventing or treating leukotriene-related diseases. The prevention also provides a pharmaceutical composition containing same and a method for preventing or treating leukotriene-related diseases.
    Type: Application
    Filed: October 13, 2006
    Publication date: March 22, 2007
    Inventors: Hea Young Park Choo, Hyeong-Kyu Lee, Sei-Ryang Oh, Kyungseop Ahn, Gyoonhee Han, Joo Heon Kim
  • Patent number: 6911443
    Abstract: A compound of the formula (I) in which R1 is —OR11, —SR11, —SOR11, —SO2R11, —NHR11, or —NR12R13 , and R11, R12, and R13 are as defined broadly in the text. R2 is H, C1-C6alkyl, carbamoyl, or an ester group. R3 is thienyl, pyridyl optionally substituted by halogen or C1-C6alkoxy; naphthyl optionally substituted by C1-C6alkoxy; dioxane fused phenyl; dioxacyclopentane fused phenyl; or optionally substituted phenyl. Y is CH or N. A process for preparing such compounds, pharmaceutical compositions containing such compounds, and a method of treating asthma using them are also disclosed and claimed.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: June 28, 2005
    Assignee: Bayer Aktiengesellschaft
    Inventors: Takeshi Yura, Arnel B. Concepcion, Gyoonhee Han, Makiko Marumo, Hiroko Yoshino, Norihiro Kawamura, Toshio Kokubo, Hiroshi Komura, Yingfu Li, Timothy B. Lowinger, Muneto Mogi, Noriyuki Yamamoto, Nagahiro Yoshida, Scott Miller, Margaret A. Popp, Aniko M. Redmann, Martha E. Rodriguez, William J. Scott, Ming Wang
  • Publication number: 20040054179
    Abstract: A compound of the formula (I) wherein R1 is —X—R4, an optionally substituted heterocyclic residue, an optionally substituted carbocyclic residue or optionally substituted condensed ring moiety; X is CR5R6, O, S, SO, SO2 or NR7; Y is CH or N; R2 is H, an optionally substituted C1-C10 alkyl,etc.; R3 is an optionally substituted aryl, or an optionally substituted heteroaryl, etc.; R4 is an optionally substituted aryl, an optionally substituted heteroaryl, etc.; R5, R6, and R7 can be identical or different and represent H, an optionally substituted C1-C10 alkyl, etc. The compound has an excellent anti-allergic activity and the like.
    Type: Application
    Filed: February 14, 2003
    Publication date: March 18, 2004
    Inventors: Takeshi Yura, Arnel b Concepcion, Gyoonhee Han, Makiko Marumo, Hiroko Yoshino, Norihiro Kawamura, Toshio Kokubo, Hiroshi Komura, Yingfu Li, Timothy B LOwinger, Muneto Mogi, Noriyuki Yamamoto, Nagahiro Yoshida, Scott Miller, Margaret A Popp, Aniko M Redmann, Martha E Rodriguez, William J Scott, Ming Wang
  • Patent number: 6380408
    Abstract: Novel sulfur-containing analogs of 1&agr;,25-dihydroxy vitamin D3 are provided. These analogs are synthesized in a convergent manner by joining A-ring and C,D ring fragments. Each analog with 1&agr;,3&bgr;-substituent stereochemistry shows a pharmacologically desirable combination of high antiproliferative and high transcriptional activities in vitro and also low calcemic activity in vivo.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: April 30, 2002
    Assignee: The Johns Hopkins University
    Inventors: Gary H. Posner, Jae-Kyoo Lee, Qiang Wang, Kenneth R. Crawford, Gyoonhee Han